Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …

Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …

Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to
directly recognize and kill tumour cells,–. These strategies are limited by the emergence of …

Within the tumour microenvironment, CD4+ T cells can promote or suppress antitumour
responses through the recognition of antigens presented by human leukocyte antigen (HLA) …

Acoustic tweezers provide an effective means for manipulating single cells and particles in a
high-throughput, precise, selective and contact-free manner. The adoption of acoustic …

Chimeric antigen receptor (CAR) T cell therapy effectively treats human cancer, but the loss
of the antigen recognized by the CAR poses a major obstacle. We found that in vivo vaccine …

Melanoma brain metastasis (MBM) frequently occurs in patients with advanced melanoma;
yet, our understanding of the underlying salient biology is rudimentary. Here, we performed …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) is a
negative modulatory signaling pathway for activation of T cell. It is acknowledged that PD …